SLDB
Price
$6.76
Change
+$0.53 (+8.51%)
Updated
Jul 23 closing price
Capitalization
524M
SRPT
Price
$13.32
Change
-$0.29 (-2.13%)
Updated
Jul 23 closing price
Capitalization
1.31B
6 days until earnings call
Interact to see
Advertisement

SLDB vs SRPT

Header iconSLDB vs SRPT Comparison
Open Charts SLDB vs SRPTBanner chart's image
Solid Biosciences
Price$6.76
Change+$0.53 (+8.51%)
Volume$1.43M
Capitalization524M
Sarepta Therapeutics
Price$13.32
Change-$0.29 (-2.13%)
Volume$9.1M
Capitalization1.31B
SLDB vs SRPT Comparison Chart in %
Loading...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLDB vs. SRPT commentary
Jul 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a Buy and SRPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 24, 2025
Stock price -- (SLDB: $6.76 vs. SRPT: $13.32)
Brand notoriety: SLDB: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 83% vs. SRPT: 120%
Market capitalization -- SLDB: $524M vs. SRPT: $1.31B
SLDB [@Biotechnology] is valued at $524M. SRPT’s [@Biotechnology] market capitalization is $1.31B. The market cap for tickers in the [@Biotechnology] industry ranges from $295.06B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, SLDB is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 4 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).

  • SLDB’s TA Score: 4 bullish, 4 bearish.
  • SRPT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SRPT is a better buy in the short-term than SLDB.

Price Growth

SLDB (@Biotechnology) experienced а +21.15% price change this week, while SRPT (@Biotechnology) price change was -27.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.15%. For the same industry, the average monthly price growth was +22.17%, and the average quarterly price growth was +31.45%.

Reported Earning Dates

SLDB is expected to report earnings on May 15, 2025.

SRPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+8.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($1.31B) has a higher market cap than SLDB($524M). SLDB YTD gains are higher at: 69.000 vs. SRPT (-89.045). SRPT has higher annual earnings (EBITDA): -106.51M vs. SLDB (-136.83M). SRPT has more cash in the bank: 523M vs. SLDB (307M). SLDB has less debt than SRPT: SLDB (23.6M) vs SRPT (1.34B). SRPT has higher revenues than SLDB: SRPT (2.23B) vs SLDB (0).
SLDBSRPTSLDB / SRPT
Capitalization524M1.31B40%
EBITDA-136.83M-106.51M128%
Gain YTD69.000-89.045-77%
P/E RatioN/A27.21-
Revenue02.23B-
Total Cash307M523M59%
Total Debt23.6M1.34B2%
FUNDAMENTALS RATINGS
SLDB vs SRPT: Fundamental Ratings
SLDB
SRPT
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
3797
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for SRPT (60). This means that SLDB’s stock grew somewhat faster than SRPT’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SRPT (100). This means that SLDB’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (94) in the Biotechnology industry is in the same range as SLDB (97). This means that SRPT’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for SRPT (97). This means that SLDB’s stock grew somewhat faster than SRPT’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SRPT (100). This means that SLDB’s stock grew significantly faster than SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBSRPT
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
62%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 8 days ago
74%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JNGIX76.960.63
+0.83%
Janus Henderson Growth And Income D
JEEIX16.88N/A
N/A
JHancock Infrastructure I
JHSGX29.90N/A
N/A
JHancock U.S. Growth R4
FIFOX24.67N/A
N/A
Fidelity Advisor Founders A
RIERX12.92N/A
N/A
RBC International Equity R6

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with BEAM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+8.51%
BEAM - SLDB
50%
Loosely correlated
+2.88%
EDIT - SLDB
48%
Loosely correlated
+2.98%
ALLO - SLDB
46%
Loosely correlated
+16.90%
CRSP - SLDB
46%
Loosely correlated
+3.35%
CRBU - SLDB
45%
Loosely correlated
+4.64%
More

SRPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRPT has been loosely correlated with ALZN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SRPT jumps, then ALZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRPT
1D Price
Change %
SRPT100%
-2.17%
ALZN - SRPT
49%
Loosely correlated
-5.94%
AXON - SRPT
43%
Loosely correlated
-2.15%
SYRE - SRPT
41%
Loosely correlated
+8.00%
SLDB - SRPT
40%
Loosely correlated
+8.51%
ARVN - SRPT
39%
Loosely correlated
+3.83%
More